Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma

Guoli Yao; De Zhou; Meng Zhou; Changqian Bao; Donghua He; Li Li; Jingjing Zhu; Jinsong He; Jimin Shi; Weiyan Zheng; Zhen Cai; He Huang; Xiujin Ye; Wanzhuo Xie

Clinical analysis and prognostic significance of L-asparaginase containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma

Int J Clin Exp Med. 2015 Jun 15;8(6):9374-83. eCollection 2015.

Authors

Guoli Yao¹, De Zhou², Meng Zhou², Changqian Bao², Donghua He², Li Li², Jingjing Zhu², Jinsong He², Jimin Shi², Weiyan Zheng², Zhen Cai², He Huang², Xiujin Ye², Wanzhuo Xie²

Affiliations

¹ Department of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China ; Department of Hematology, The First People's Hospital of Yuhang District Hangzhou 311100, Zhejiang, China.
² Department of Hematology, The First Affiliated Hospital of Medical School of Zhejiang University No.79 Qingchun Road, Hangzhou 310003, Zhejiang, China.

PMID: 26309599
PMCID: PMC4537992

Abstract

Objective: To observe the clinical effects and adverse reactions, and analyze the clinical significance of L-asparaginase (L-ASP) containing multidrug chemotherapy regimen in incipient peripheral T-cell lymphoma (PTCL).

Methods: A retrospective analysis was conducted of 102 patients with incipient PTCL who received L-ASP containing multidrug chemotherapy regimens or not in our hospital from January 2010 to December 2013. Complete remission (CR) rate, partial remission (PR) rate, overall remission (OR) rate, progression free survival (PFS), overall survival (OS) and adverse reactions were compared.

Results: Patients who received L-ASP containing multidrug chemotherapy (L-ASP group) had higher OR rate than those who received L-ASP-free ones (non L-ASP group) (83.3% vs 61.7%, P=0.016), particularly those at phase III/IV (82.4% vs 54.0%, P=0.007) and with an international prognostic index (IPI) score of ≥2 (82.1% vs 50.0%, P=0.006). The median survival time (OS) was 10.5 months (range, 1-47months) in L-ASP group, while 13 months (range, 0.3-68 months) in non L-ASP group, and they had no statistically significance (P=0.754). Similarly, the progression free survival time(PFS)was 10 months (range, 1-47 months) in L-ASP group,while 11 months (range, 0.3-68 months) in non L-ASP group, also had no statistically significance (P=0.414). The 3-year OS rate of L-ASP group and non L-ASP group were 48.9% and 65.0% , respectively (P=0.974) and the 3-year PFS rate of L-ASP group and non L-ASP group were 40.8% and 61.0%, respectively (P=0.479). They all had no statistically significance. The L-ASP group had more adverse reactions than the non L-ASP group, though most of them were mild and could be improved by symptomatic and supportive care.

Conclusion: L-ASP containing multidrug chemotherapy regimen in incipient PTCL showed a better short-term effect and controllable adverse reactions. A large prospective clinical trial of use L-ASP in first-line treatment of PTCL is worthy of further research and investigation.

Keywords: Lymphoma; adverse reaction; effect; l-asparaginase; peripheral t-cell; safety.